Predict your next investment

RoosterBio company logo
HEALTHCARE | Biotechnology
roosterbio.com

See what CB Insights has to offer

Founded Year

2012

Stage

Loan | Alive

Total Raised

$30.6M

Last Raised

$1.5M | 2 yrs ago

About RoosterBio

RoosterBio is a cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high-volume and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with engineered media systems.

RoosterBio Headquarter Location

5295 Westview Drive 275

Frederick, Maryland, 21703,

United States

301-678-9497

Latest RoosterBio News

Frederick’s RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer

Oct 5, 2021

Biohealth Innovation Tuesday, October 5, 2021 Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies FREDERICK, Md., Oct. 5, 2021 /PRNewswire-PRWeb/ -- RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) bioprocess systems for cell and gene therapy product developers, today announced Timothy M. Kelly, PhD, has joined the company as Chief Executive Officer and as a member of the Board of Directors. Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies in the U.S. and Europe. "We are excited to welcome Tim to the RoosterBio team! Tim brings extensive leadership experience and a proven track record growing small companies into highly sustainable businesses. What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies," said Jon A. Rowley, PhD, founder and chief product officer of RoosterBio. "I am confident Tim will be an outstanding leader for this business and will help us achieve the aggressive growth plans that we have for RoosterBio." Dr. Kelly stated," RoosterBio has established a position of true technology leadership in the field of MSCs. I am incredibly excited to help Jon and the RoosterBio team expand upon this foundation and translate our innovative technologies into end-to-end bioprocess solutions for the development and manufacture of MSC and extracellular vesicle therapeutics." Dr. Kelly most recently was President of Manufacturing at Asklepios Biopharmaceutical, Inc., which was acquired by Bayer in October 2020 for up to $4 billion. For 15 years prior, he was with KBI Biopharma, Inc., culminating in his leadership role as President and Chief Executive Officer. Dr. Kelly also served as Chairman of Selexis SA while leading the integration of Selexis and KBI Biopharma. He began his corporate experience at Diosynth Biotechnology (formerly Covance Biotechnology Services Inc.). He has been the recipient of several awards, including Life Sciences Company of the Year from Triangle Business Journal, and is an active member in multiple professional organizations. Dr. Kelly earned his PhD in molecular genetics and biochemistry from George State University and his BA in biology from College of the Holy Cross. About RoosterBio RoosterBio, Inc., is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field. Visit  http://www.roosterbio.com . Media Contact Kim Hastings, Marketing Operations Associate, RoosterBio, Inc., (301) 200-5366, This email address is being protected from spambots. You need JavaScript enabled to view it.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RoosterBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RoosterBio is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

RoosterBio Patents

RoosterBio has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Stem cells
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2015

7/13/2021

Stem cells, Cell biology, Clusters of differentiation, Biotechnology, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/12/2015

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/13/2021

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Stem cells, Cell biology, Clusters of differentiation, Biotechnology, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

RoosterBio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

RoosterBio Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.